Loading clinical trials...
Loading clinical trials...
Pilot Phase I HER-2 Pulsed DC Vaccine to Prevent Recurrence for Patients With HER-2 Driven High Risk Invasive Breast Cancer Post Neoadjuvant Chemotherapy
Conditions
Interventions
HER-2 pulsed Dendritic Cell Vaccine
Locations
2
United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Start Date
April 8, 2014
Primary Completion Date
February 1, 2019
Completion Date
February 21, 2024
Last Updated
August 2, 2024
NCT04541381
NCT05468034
NCT03137095
NCT04852887
NCT06393374
NCT07547774
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions